Furthermore, there has been an increasing trend in the number of reports on IMI/CIL-related AEs over the years, which may be attributed to either increased drug usage or heightened enthusiasm among medical professionals in reporting such AEs.
← all excerpts
Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database.
1
—
—